Tempest Therapeutics, Inc.
TPST
$10.03
$0.6757.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.57M | 13.22M | 13.55M | 13.70M | 13.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.37M | 44.99M | 42.03M | 35.62M | 31.66M |
| Operating Income | -43.37M | -44.99M | -42.03M | -35.62M | -31.66M |
| Income Before Tax | -43.10M | -44.80M | -41.84M | -35.52M | -31.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.10 | -44.80 | -41.84 | -35.52 | -31.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.10M | -44.80M | -41.84M | -35.52M | -31.75M |
| EBIT | -43.37M | -44.99M | -42.03M | -35.62M | -31.66M |
| EBITDA | -43.09M | -44.62M | -41.64M | -35.20M | -31.25M |
| EPS Basic | -14.93 | -18.37 | -19.84 | -20.45 | -21.38 |
| Normalized Basic EPS | -9.33 | -11.48 | -12.40 | -12.78 | -13.36 |
| EPS Diluted | -14.93 | -18.37 | -19.84 | -20.45 | -21.38 |
| Normalized Diluted EPS | -9.33 | -11.48 | -12.40 | -12.78 | -13.36 |
| Average Basic Shares Outstanding | 12.38M | 10.31M | 8.58M | 6.93M | 6.03M |
| Average Diluted Shares Outstanding | 12.38M | 10.31M | 8.58M | 6.93M | 6.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |